Biogen Inc. announced on Wednesday that it has halted the development and marketing of the Aduhelm 100 mg/mL injection for intravenous use. This also means that the ENVISION study, which aimed to verify the clinical benefits of Aduhelm for early Alzheimer’s Disease patients, will be discontinued.
Biogen clarified that this decision was not based on any issues regarding safety or effectiveness. Rather, this move is a reprioritization of their resources in the Alzheimer's disease field, where they anticipate both immediate and long-term growth.
In lieu of Aduhelm, Biogen will redirect its resources to further develop Leqembi, which was authorized for Alzheimer’s Disease treatment in January of this year. The company also plans to explore the development of new treatment methods.
Following the termination of the Aduhelm program, a significant portion of the remaining resources will be reinvested into Biogen’s Alzheimer’s Disease franchise, according to the company's statement.
